A cute coronary syndromes (ACS) are a leading cause of illness and death in Australia. Around 75 000 Australians are hospitalised for ACS each year, with $8 billion spent annually on related inpatient care.
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While mortality caused by ACS is declining because of better control of coronary risk factors and the introduction of new treatments, 2 at least 10 000 Australians still die each year as the result of ACS. 1 The spectrum of ACS includes unstable angina, where atherosclerotic plaque rupture leads to arterial occlusion and myocardial ischaemia, and myocardial infarction, where ischaemia progresses to myocardial cell necrosis. Further classification into ST elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI) is based on electrocardiographic (ECG) findings. Overall, the rate of inhospital major adverse cardiac events caused by ACS (death, cardiac arrest, recurrent myocardial infarction, worsening heart failure, major bleeding or stroke) approaches 30% for STEMI and 20% for NSTEMI. 3 Patients with unstable angina are also at increased risk of death and subsequent myocardial infarction, even in the absence of myonecrosis. 4 Diagnosing ACS is challenging in primary care as well as in the tertiary setting; 15% of patients who experience an ACS initially contact their general practitioner. 5 The diagnosis of ACS in primary care is not always straightforward; signs and symptoms alone are neither sensitive nor specific in the prehospital population, 6 and the validity of clinical prediction rules for ACS in primary care populations is limited. 7 Given these limitations, there are potential benefits to using cardiac biomarkers in primary care. Cardiac troponin (cTn) is the main biomarker in patients who present with possible ACS. A change in cTn levels signifies myocardial necrosis with high sensitivity and specificity, and allows differentiation of myocardial infarction from unstable angina. 8 Examples of the benefits of cTn as a biomarker in primary care include the diagnosis of myocardial infarction where it was not suspected initially because of atypical presenting features; the exclusion of myocardial infarction in low-risk patients; and the conservation of resources by avoiding hospital referral. 9 However, there are pitfalls and practical considerations associated with cTn as a biomarker in primary care. Compared with those presenting directly to hospital, patients with ACS who first consult a community physician have longer prehospital delay 10 and decreased survival.
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Several authors have expressed concern that GP cTn requests contributes to these outcomes, 12, 13 and there is also evidence of overinterpretation of positive results 12 and over-reliance on negative results.
14 There can also be problems with follow-up if the test results are notified after normal practice hours.
In this study, we examined a population of patients with possible symptoms of ACS who underwent GP-initiated cTn testing. We compared the incidence of ACS and associated adverse outcomes with those in patients who had presented to hospital for cTn testing. We also explored GPs' knowledge of the limitations of the usefulness of cTn testing, and the influence of cTn test results on their diagnosis and hospital referral practices.
Abstract
Objective: To examine the use of cardiac troponin (cTn) testing for acute coronary syndrome (ACS) diagnosis in primary care. Data sources and measurement GP cohort: laboratory data. A research assistant at each laboratory obtained consecutive cTn test results requested by GPs, using the practice address to establish GP status.
GP cohort: survey data. Laboratory research assistants approached requesting GPs for de-identified details about the clinical scenario leading to the cTn test request and the clinical course after notification of the result. GPs were contacted within 1 week of testing, with telephone follow-up to non-responders 1 week after the initial contact. Information was collected on a one-page survey sent and returned by fax, with an information sheet and consent form concurrently sent to the doctor. Risk stratification was undertaken using elements of the National Heart Foundation/Cardiac Society of Australia and New Zealand (NHF/ CSANZ) criteria that could be readily assessed during a general practice consultation. 15 GP cohort: linked data. Linked data were obtained from the Department of Health Western Australia Data Linkage System (WADLS) for all patients for a minimum 12-month period after the date of their test, irrespective of whether their GP had responded to the survey. The final cTn test included in our study was performed in September 2010, and follow-up continued until October 2011. Outcomes were defined according to standardised definitions recommended for Australasian ACS research. 16 Specific diagnosis and procedure codes were selected from the International Classification of Diseases, 10th revision, Australian modification (ICD-10 AM) 17 and the Australian Classification of Health Interventions. 18 Linkage and extraction were performed in November 2013 to compensate for delay in updating of Department of Health records. Records were excluded from analysis if no principal diagnosis was stated, or if the presenting symptom or principal diagnosis was insufficiently specific to allow classification. Duplicate records with more than one hospital admission for the same patient on the same day were treated as one admission for the purposes of statistical analysis.
ED cohort. Clinical presentations and outcomes in the GP survey cohort were compared with an ED cohort using the Multiple Infarct Markers in Chest Pain (MIMIC) study dataset. 19 This prospective cohort study was conducted between September 2008 and June 2009 in two tertiary and three general hospitals in urban Perth. The urban catchment areas of the hospitals were similar to those of the collection centres in the GP survey cohort. Participants were a representative sample of patients undergoing evaluation for possible ACS with serial cTn testing. Patients were excluded if they were less than 18 years of age or pregnant, and where ECG criteria had indicated urgent reperfusion therapy. 
Results

Participants
Box 1 depicts participant flow through the study. There were no significant differences between included and excluded patients with respect to age or sex (each P > 0.10).
Descriptive data
Box 2 presents the characteristics of the 124 patients in the GP cohort for whom survey data were available. The most common presentation was pain typical of cardiac ischaemia (55.6%).
Data on coronary risk factors were available for 104 GP cohort patients. Six patients (5.7%) were at high risk of ACS according to the NHF/ CSANZ risk stratification framework, 15 with a combination of typical symptoms and diabetes. A further 65 patients (62.5%) were at intermediate risk of ACS, including 40 (38.5%) over 65 years of age, 16 (15.4%) with various combinations of hyperlipidaemia, a family history of coronary heart disease (CHD), smoking history and hypertension, and nine patients (8.7%) with diabetes and atypical symptoms of ACS.
The median time from specimen collection to sample registration at the processing laboratory was 31 minutes (range, 0 mine1465 min). This interval depended on the location of the collection centre; centres co-located with laboratories had the shortest intervals. Overall, the median time between specimen collection and availability of the test result was 128 minutes (range, 23min e 1466 min).
Before receiving the test results, most GPs (80/124, 64.5%) rated the likelihood of ACS in their patient as low (less than 5%). This proportion increased after the results were received (to 110/124, 88.7%). A 
The prevalence of smoking (P ¼ 0.01), hypertension (P ¼ 0.02), dyslipidaemia (P ¼ 0.03) and a personal or family history of CHD (P < 0.001) were all significantly greater in the GP survey group than in the MIMIC dataset cohort (Box 2).
Outcome data GP cohort: linked data. Linked data were available for 361 tests performed for 355 patients; data for eight patients could not be linked because of insufficient identifying information.
There were 176 presentations to hospital with a cardiovascular symptom or diagnosis during follow-up, whether by presentation to an ED (112 presentations) or by direct admission (64 presentations). Of the 112 presentations to an ED in the GP cohort, 87 were assigned a triage category of 1 or 2, indicating that they required medical review immediately or within 10 minutes.
In total, 94 of 355 of the GP cohort (26.5%) presented at least once to a hospital during follow-up with cardiovascular diagnoses (Box 3 and Box 4). Twenty-one of these 94 patients (22.3%) presented to a hospital within 48 hours of testing. The median time from testing to first presentation was 33 days (range, 0 dayse551 days).
Within 48 hours of testing, six of the GP cohort (1.7%) had been diagnosed with an ACS; the median time from specimen collection to hospital presentation for these patients was 382 minutes (range, 80 mine1312 min). Box 5 lists the components of delay for this group. Death outside hospital due to cardiovascular cause (1); cardiac arrest (1); cardiogenic shock (1); ST elevation myocardial infarction (1); non-ST elevation myocardial infarction (5); acute myocardial infarction (9); unstable angina (9)* Coronary heart disease, not otherwise specified 8
Cardiomyopathy 1
Heart failure 5
Arrhythmia 6
Supraventricular tachycardia (1); ventricular tachycardia (1); atrial fibrillation (1); atrioventricular block, 2nd degree (1); bradycardia (1); cardiac arrhythmia, other (1)
Other cardiovascular diagnosis 47
Aortic valve stenosis (1); hypertensive (6); chest pain, anterior chest wall (3); chest pain on breathing (26); chest pain unspecified (4); syncope (1); dizziness (3); palpitations (2); dyspnoea (1)
* No hospital admission data were collected for four patients with unstable angina. u
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55-year-old patient), one cardiac arrest in a patient with known CHD, and one episode of cardiogenic shock. During the follow-up period, 27 of 355 patients (7.6%) had at least one ACS. The median time to presentation with the first ACS was 42 days (range, 0 dayse498 days).
GP cohort: survey and linked data. For the 124 patients with both linked and survey data, there were 45 presentations to hospital, including 18 ACSs in 11 patients. Six occurred within 1 month of the cTn test, and in each case symptoms had commenced at least 48 hours before the test.
ED cohort. Three hundred and sixty-eight patients of the 1758 in the MIMIC dataset (20.9%) received a discharge diagnosis of ACS, significantly more than the 13 patients (3.7%) with an ACS in the GP cohort (P < 0.001 15 In an ED, such patients would not be considered safe for discharge home until further investigations and monitoring had determined a lower risk level. 15 The patients in our study, in contrast, would have been largely unmonitored in the community for some hours while awaiting their test results, as well as during the days following a negative result.
The finding that patients undergoing GP-initiated cTn testing were not low-risk was unexpected, and there may have been other factors not detected by the survey that reduced the risk status of patients. Obtaining comprehensive data on individual risk factors may have helped to resolve this question, including ECGs, quantitative blood pressure and lipid profiles, and the results of earlier invasive investigations for CHD. This information would also allow application of additional cardiovascular risk scoring tools and improve the generalisability of our study, although this would risk patient identification and reduced participation because of the longer survey duration.
Turnaround times in this study indicated that there was a substantial delay between presentation to a GP and cTn results becoming available. Particularly concerning was the median delay of more than 5 hours in those patients who were subsequently confirmed to have an ACS and who had presented within 48 hours of symptom onset, when the risk of complications is greatest. 8 While the Royal Australian College of General Practitioners Standards 20 require evidence of systems that ensure timely response to pathology results, there is evidence from the Threats to Australian Patient Safety (TAPS) study 21 and elsewhere 9 which suggests that this does not always occur.
GPs may not fully understand the limitations of cTn testing, as 23.4% of tests were ordered within 12 hours of symptom onset (Box 2), at which point the test may be insufficiently sensitive. While all major guidelines groups recommend serial testing to exclude ACS in this context, 4, 8, 22 no serial testing was performed by GPs in our study.
In many cases, the test result did not alter patient management. Some tests were clearly ordered in response to a patient request, and one GP commented that "the test was mainly arranged to satisfy the patient that this was unlikely cardiac". It is worth noting that a negative cTn test in this context may not have resolved patient anxiety, as many patients presented to a hospital within hours of receiving a negative test.
GPs are in a difficult situation. 23 Failure to accept any uncertainty may lead to unnecessary investigations and referrals, themselves potential causes of patient harm and unnecessary system costs. However, based on the results of our study, we concur with previous authors in this journal 7, 9 who have suggested that GPs should maintain a high threshold for requesting cTn testing and refer patients promptly to hospital for assessment when clinical features suggest a diagnosis of ACS. Possible ACS is one setting in which GPs can justifiably advise patients to present to a hospital, rather than undertaking investigations in primary care. 
